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Introduction
Over the last 10 years, studies of T-cell-mediated re-
sponses in vitro have clearly demonstrated that some
cancer patients have (mainly but not exclusively) CD8+
cytolytic T-lymphocytes (CTL) that can recognize spe-
cifically autologous tumor cells [1]. Until 1991, how-
ever, no CTL-defined tumor antigen was characterized
in molecular terms in humans. With the development
of new approaches based on recent advances in our
basic understanding of the processes involved in anti-
gen recognition by T-cells [2, 3] the past 5 years have
witnessed the molecular definition of more than a
dozen human tumor antigens recognized by CD8+
T-cells.
While studies in murine tumor model systems sug-
gested that peptides derived from mutated gene pro-
ducts would be the primary candidates for tumor anti-
gens recognized by CTL [4-7], most of the human
tumor-associated antigens defined thus far are derived
from normal (non-mutated) proteins. Since these anti-
gens have been identified by virtue of their recognition
by autologous CTL clones, it is now evident that the
field of tumor immunology is more closely related to
autoimmunity (or immune recognition of serf proteins)
than to immune responses to foreign antigens. In this
review, we first discuss the strategies used to identify
tumor-associated, CTL-defined peptide antigens. We
then describe some of the antigens that are currently
considered as potential targets for peptide-based vac-
cines. Finally, we briefly summarize the first attempts to
elicit specific CTL responses in cancer patients with
such vaccines.
Strategies to identify tumor-associated antigens
CD8+ CTL recognize antigenic peptides produced by
the degradation of intracellular proteins that are trans-
ported to the cell surface in association with major
histocompatibility complex (MHC) class I molecules
(i.e., HLA-A, -B and -C in humans). In normal cells as
well as in tumor cells, most of the MHC class I mol-
ecules expressed at the cell surface are associated with
peptides produced by the degradation of normal pro-
teins. Moreover, there is a large number (> 10.000) of
different peptides associated with MHC class I mol-
ecules expressed by a given cell. Finally, the set of dif-
ferent peptides presented at the cell surface varies
between MHC class I isoforms (or alleles), e.g., HLA-
Al and HLA-A2 [8]. Because of the extreme diversity
of peptides naturally associated with MHC class I mol-
ecules, the identification of the antigenic peptides natu-
rally recognized by tumor-specific CTL is not a trivial
task, and three new methods have been developed for
that purpose.
The first method is based on a genetic approach
whereby the gene encoding the tumor antigen is iden-
tified by testing appropriate target cells transfected
with recombinant DNA libraries or cDNA libraries
prepared from tumor cells for recognition by autolo-
gous tumor-specific CTL clones [9-11]. Once the gene
has been identified, the region encoding the antigenic
peptide can be narrowed down by transfecting gene
fragments. The amino acid sequence deduced from the
nucleotide sequence of this region is used to produce
synthetic oligopeptides which are then tested in a target
cell sensitization assay for recognition by the original
tumor-specific CTL clones. The rationale for such an
approach is based on the demonstration that synthetic
peptides can mimic endogenously derived peptides in
appropriate CTL assays in vitro.
The same rationale has been applied in the develop-
ment of a second method based on a biochemical ap-
proach in which peptides associated with MHC class I
molecules expressed by tumor cells are extracted and
fractionated by high pressure liquid chromatography
[12, 13]. The peptide fractions are then tested in a tar-
get cell sensitization assay for recognition by tumor
specific CTL clones. After several steps of fractiona-
tion, the sequences of the peptides recognized by CTL
are obtained by the use of tandem mass spectrometry
[14].
While these two approaches rely on the availability
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of tumor-specific CTL clones derived from T-cell
populations of cancer patients, a third method is based
on the induction of CTL responses in vitro using nor-
mal peripheral blood lymphocytes stimulated with syn-
thetic peptides corresponding to linear amino acid
sequences of a known tumor-associated protein and
which are selected on the basis of their ability to bind to
a particular MHC class I isoform. Once peptide-spe-
cific CTL clones are obtained, they are used to assess
whether the same peptides are presented at the surface
of tumor cells upon endogenous processing of the
tumor-associated protein [15-18].
CTL-defined tumor antigens
The first human rumor antigen to be defined in molecu-
lar terms was identified using the genetic approach
mentioned above [9]. Because the CTL clone used to
identify the antigen was directed against autologous
melanoma cells, the gene encoding the antigen was
called MAGE-1 ('NT for melanoma and 'AGE' for
antigen). However, the gene is not only expressed in
some melanomas, but also in a significant proportion of
other tumors, including non-small cell lung carcino-
mas, mammary carcinomas, head and neck squamous
cell carcinomas and bladder carcinomas [11,19-21]. In
contrast, MAGE-1 is silent in normal tissues, except
testis. The CTL-defined antigens identified thus far are
two distinct nonapeptides which associate with HLA-
Al and HLA-Cwl6 molecules, respectively [22, 23].
MAGE-1 belongs to a family of 12 genes located on
chromosome X [24]. Among this family, MAGES also
encodes CTL-defined antigens, which have been iden-
tified as nonapeptides or decapeptides associated with
HLA-A1, HLA-A2 or HLA-B44, respectively [15-18,
25]. It should be stressed that the sequences of genes
MAGE-1 and MAGES are identical in tumor cells and
normal cells. Interestingly, the frequency of MAGE-1
and MAGES expression in malignant melanoma is sig-
nificantly higher in metastatic lesions than in primary
lesions [26]. Both genes are silent in melanocytes, in
benign and in dysplasic nevi as well as in in situ mela-
nomas. In primary melanomas, the frequency of ex-
pression of both genes increases with tumor thickness
[26]. Similarly, a higher frequency of MAGE gene
expression in invasive than in superficial lesions is
found in primary transitional cell carcinomas of the
bladder [21]. As the function(s) of MAGE-1 and
MAGES gene products is unknonw, it is unclear
whether they play any role in tumor progression. More-
over, further work is needed to ascertain whether
MAGE-1 and/or MAGES expression is homogeneous
in a given tumor. It should also be kept in mind that
there is presently no way to quantitate the amount
of antigenic peptides derived from the MAGE-1 and
MAGES proteins that are displayed on the surface
of tumor cells. Obviously, these limitations in our
knowledge should be taken into account in the future
development of peptide-based vaccines.
Other antigens recognized by melanoma-specific
CTL clones have been identified by the genetic ap-
proach. Since the genes encoding these antigens, like
the MAGE genes, are silent in normal tissues, except
testis, and expressed in different tumor types, they have
been designated BAGE and GAGE [27, 28]. The anti-
genic peptides identified thus far are associated with
HLA-Cwl6 and HLA-Cw6 molecules, respectively.
Because these two HLA alleles are relatively rare in the
Caucasian population, the usefulness of these antigenic
peptides for cancer vaccines has yet to be defined.
In contrast to the antigens described above, another
category of CTL-defined tumor antigens is lineage-spe-
cific, i.e., the genes involved are expressed in both nor-
mal and cancer cells of the same histological type. The
prototypes of such antigens are the antigenic peptides
derived from proteins, such as tyrosinase [29-32],
gplOO [14, 33] gp75 [34] and Melan-A/MART-1 [35,
36] that are expressed in cells of the melanocytic lin-
eage (i.e., melanocytes and melanomas). Interestingly,
the majority of the peptides defined thus far are asso-
ciated with HLA-A2, which is expressed in about 50%
of the Caucasian population. Moreover, the great ma-
jority of malignant melanomas express the genes en-
coding tyrosinase and Melan-A, and the expression of
the proteins appears homogeneous within individual
tumors. Altogether, these features make such antigenic
peptides good candidates for peptide-based vaccines in
melanoma. Obviously, there is a risk of generating CTL
responses directed against both melanocytes and mela-
noma cells with such vaccines. In this context, it is note-
worthy that the occurrence of vitiligo (presumably as a
result of T-cell mediated elimination of melanocytes) in
melanoma patients is associated with prolonged sur-
vival [37, 38]. It thus appears justified to include mela-
nocyte lineage-specific peptides defined by CTL in the
construction of melanoma vaccines.
As stated previously, peptides derived from cellular
oncogene products were considered attractive candi-
dates for human CTL-defined tumor antigens since the
corresponding proteins are often mutated in tumor
cells. Indeed, peptides derived from mutated forms of
p21 ras or p53 have been identified using the approach
based on in vitro CTL responses induced by selected
synthetic peptides [39-41]. With few exceptions, how-
ever, the CTL clones obtained under these conditions
did not recognize tumor cells expressing the relevant
mutated protein, thus suggesting that no (or too few)
endogenously derived peptides corresponding to the
synthetic peptides used for CTL induction in vitro were
present at the tumor cell surface.
In contrast, there is evidence that CTL-defined anti-
gens can be derived from the HER-2/neu oncogene
product [42, 43]. Interestingly, the identified peptides
correspond to the normal HER-2/neu sequence. Since
the HER-2/neu product is often overexpressed in tu-
mor cells, it is likely that quantitative, rather than quali-
tative, differences in endogenously produced peptides
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are responsible for the specific CTL recognition of
tumor cells as compared to normal cells. Tumor types
that have been shown to be recognized by HER-2/neu
peptide-specific CTL include ovarian, breast and non-
small cell lung carcinomas [44,45].
From this brief survey of CTL-defined tumor anti-
gens, which is by no means comprehensive, it should be
evident that a large number of antigenic peptides have
recently been identified which are potential candidates
for peptide-based cancer vaccines. Indeed, this infor-
mation is already being used to design phase I clinical
trials based on the use of single tumor-associated pep-
tide antigens.
Clinical prospects
The molecular characterization of tumor antigens
potentially able to be recognized by CTL opens up new
strategies for attempts at active immunization in human
cancer. In contrast to the various types of cancer vac-
cines used in the past, there is now the possibility to use
tailor-made vaccines that only contain relevant tumor
antigens. The first step consists of determining for indi-
vidual cancer patients the panel of tumor-associated
peptides presumably expressed by their tumor cells.
This can be done' by assessing the expression of the
relevant genes or gene products in a small tumor sam-
ple. In combination with the determination of the
MHC class I alleles expressed in the patient, this infor-
mation is used to select the relevant synthetic peptides
to be included in a vaccine preparation.
For practical reasons, the current phase I clinical
trials based on the use of CTL-defined peptides have
involved administration of peptide alone. While some
positive responses have been reported [46,47], it is evi-
dent that peptide antigens demonstrate excellent safety
but also weak immunogenicity. Thus, the need for im-
proving the immunogenicity of peptides has renewed
interest in adjuvants. Evaluation of these new vaccine
strategies is still at a very early stage, and it is likely that
a relatively large number of phase I clinical trials will be
necessary to evaluate the various procedures that are
being proposed. Moreover, careful monitoring of spe-
cific CTL responses elicited by peptide-based vaccines
is necessary to assess the efficacy of the immunization
procedure in individual patients. In this respect, it
should be kept in mind that little is known on the ability
of adjuvants to augment CTL responses to peptide anti-
gen in humans. Because alum adjuvants increase anti-
body responses rather than T-cell responses, several
new adjuvants are currently under evaluation in clinical
trials [48]. The use of appropriate adjuvants in peptide-
based cancer vaccines may be particularly crucial since
there is increasing evidence for alterations in the im-
mune responsiveness of cancer patients [49].
An alternative approach for the generation of CTL
in vivo is the administration of autologous dendritic
cells loaded with the corresponding peptide antigens.
Dendritic cells are often referred to as 'professional'
antigen-presenting cells since their ability to initiate
antigen-specific T-cell responses is superior to that of
other antigen-presenting cells [50]. Based on positive
results obtained in murine tumor model systems [51],
attempts to use tumor peptide-loaded dendritic cells
have been initiated [52]. As mentioned above, the
validity of such an approach will only be established in
carefully planned clinical trials.
In summary, the recent identification of molecularly
defined tumor antigens that can be mimicked by syn-
thetic peptides provides new vaccine possibilities in
cancer. Vaccine construction can be adjusted to the
antigenic profile exhibited by individual tumors. Care-
ful investigation of immunized patients is required in
order to develop effective cancer vaccines.
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